Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

4.310 -0.040 (-0.92%)
Official Closing Price Updated: 7:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
FDA Strikes Out Amneal Pharmaceuticals' Parkinson's Disease Candidate, Stock Falls
Amneal Pharmaceuticals Inc (NYSE: AMRX) received an FDA Complete Response Letter (CRL) regarding its New Drug Application for IPX203  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Complete Response Letter for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharma Q1 Exceeds Consensus View On Strength In Complex Generics Portfolio
Via Benzinga
Recap: Amneal Pharmaceuticals Q1 Earnings
Via Benzinga
Earnings Preview: Amneal Pharmaceuticals
Via Benzinga
Expert Ratings for Amneal Pharmaceuticals
Via Benzinga
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 2023 Jefferies Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports First Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 5, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion. 
Via Benzinga
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2023 Results on May 5, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
Intercept entered a deal with Amneal, likely lining up a series of new settlements. 
Via Investor's Business Daily
Amneal Announces Strategic European Partnership with Orion Corporation
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.